Development and evaluation of a patient centered cardiovascular health education program for insured patients in rural Nigeria (QUICK - II) by Odusola, Aina Olufemi et al.
STUDY PROTOCOL Open Access
Development and evaluation of a patient
centered cardiovascular health education
program for insured patients in rural Nigeria
(QUICK-II)
Aina Olufemi Odusola
1,2*, Marleen Hendriks
1,3, Constance Schultsz
1,4, Karien Stronks
5, Joep Lange
1, Akin Osibogun
6,
Tanimola Akande
7, Shade Alli
8, Peju Adenusi
9, Kayode Agbede
10 and Joke Haafkens
11
Abstract
Background: In Sub Saharan Africa, the incidence of hypertension and other modifiable cardiovascular risk factors
is growing rapidly. Poor adherence to prescribed prevention and treatment regimens by patients can compromise
treatment outcomes. Patient-centered cardiovascular health education is likely to improve shortcomings in
adherence. This paper describes a study that aims to develop a cardiovascular health education program for
patients participating in a subsidized insurance plan in Nigeria and to evaluate the applicability and effectiveness in
patients at increased risk for cardiovascular disease.
Methods/Design: Design: The study has two parts. Part 1 will develop a cardiovascular health education program,
using qualitative interviews with stakeholders. Part 2 will evaluate the effectiveness of the program in patients,
using a prospective (pre-post) observational design.
Setting: A rural primary health center in Kwara State, Nigeria.
Population: For part 1: 40 patients, 10 healthcare professionals, and 5 insurance managers. For part 2: 150 patients
with uncontrolled hypertension or other cardiovascular risk factors after one year of treatment.
Intervention: Part 2: patient-centered cardiovascular health education program.
Measurements: Part 1: Semi-structured interviews to identify stakeholder perspectives. Part 2: Pre- and post-
intervention assessments including patients’ demographic and socioeconomic data, blood pressure, body mass
index and self-reporting measures on medication adherence and perception of care. Feasibility of the intervention
will be measured using process data.
Outcomes: For program development (part 1): overview of healthcare professionals’ perceptions on barriers and
facilitators to care, protocol for patient education, and protocol implementation plan.
For program evaluation (part 2): changes in patients’ scores on adherence to medication and life style changes,
blood pressure, and other physiological and self-reporting measures at six months past baseline.
Analysis: Part 1: content analytic technique utilizing MAXQDA software. Part 2: univariate and multilevel analysis to
assess outcomes of intervention.
Discussion: Diligent implementation of patient-centered education should enhance adherence to cardiovascular
disease prevention and management programs in low income countries.
Trial Registration: ISRCTN47894401
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Sub Saharan African (SSA) countries are currently
experiencing a rapid increase in the incidence of cardio-
vascular diseases (CVD) [1,2]. Hypertension is an impor-
tant risk factor for CVD. Poor adherence to prescribed
medication regimens or lifestyle advices can severely
compromise the effectiveness of CVD prevention and
treatment [3]. For that reason, the World Health Orga-
nization (WHO) emphasizes in a recent report that any
attempt to improve cardiovascular care should also
address the issue on non-adherence [3]. The views and
beliefs of patients regarding disease conditions and
treatment may differ from medical perceptions, and it is
well documented that patients do have significant roles
to play in adherence to medications and lifestyle mea-
sures [4-6]. Evidence to date indicates that patient edu-
cation is one of the most successful interventions to
improve adherence and patient self-management of
chronic diseases, especially if the education addresses
patients’ beliefs and concerns about the condition and
treatment, identifies social cultural and individual bar-
riers to adherence and enhances patients’ confidence in
their ability to overcome those barriers [7].
In this paper, we describe the design of a study that
has the aim to develop and test a program for cardiovas-
cular health education for patients who are enrolled in a
subsidized, community-based health insurance program
in Nigeria and are at an increased risk of developing
CVD. This study is part of the project “QUality
Improvement for Cardiovascular care Kwara (QUICK)”.
The project will be evaluated by two studies: QUICK-I
and QUICK-II. This paper describes the design of the
QUICK-II study that focuses on patient education. A
detailed description of the insurance program and the
QUICK-I study can be found elsewhere [8].
Aim of the study
The World Health Organization/International Society of
Hypertension (WHO/ISH) guidelines recommend
patient education as part of CVD prevention care [9],
but they do not provide clear recommendations on how
this education should be delivered and tailored to the
specific target groups in the region. We hypothesize that
tailored patient education will improve adherence to
cardiovascular care among patients.
For that reason, the main aims of QUality Improve-
ment Cardiovascular care Kwara II (QUICK - II) are:
1. To develop and implement a targeted cardiovascu-
lar health education program (CHEP) for patients parti-
cipating in the Hygeia Community Health Plan (HCHP)
2. To evaluate the newly developed program with
respect to its applicability and effectiveness in patients
at an increased risk for CVD
Methods
Project design
QUICK - II consist of two consecutive parts
In part 1 of the study, we will develop a stakeholder
based Cardiovascular Health Education Program
(CHEP) that is to be used to educate patients at risk of
CVD who are enrolled in a private health insurance
plan in rural Nigeria. To develop CHEP, we will use the
following step-wise approach: (i) open qualitative inter-
views will be conducted with key stakeholders in CVD
care to explore their perceptions on CVD, CVD risk fac-
tor management and CVD prevention and care. These
stakeholders include patients at risks for CVD, health-
care providers (HCP), and health insurance managers of
HCHP; (ii) on the basis of the outcomes of interviews
with patients, CHEP will be developed; (iii) supportive
strategies needed to implement CHEP successfully will
be identified on the basis of the outcomes of the inter-
views with HCP and health insurance managers.
In Part 2 of the study we aim to evaluate the effect of
CHEP through a prospective hospital-based study, using
ap r e - p o s ti n t e r v e n t i o nd e s ign. Measurements will be
conducted in a subset of patients included in QUICK -
I: those who have uncontrolled hypertension or other
CVD risk factors, or are non adherent to medication
after 12 months of treatment.
In addition, case file data will be reviewed and inter-
views with health care professionals in the participating
clinic will be held and analyzed to evaluate the feasibility
of the application of CHEP in practice.
Setting
Ogo Oluwa Hospital (OOH) in Bacita (Kwara State). A
detailed description of this setting can be found in the
accompanying paper describing the QUICK-I study
design [8].
Because part 1 and part 2 of this study have different
designs, we will describe the study procedures in differ-
ent sections.
Part 1: Development of Chep
Study Population
The study population for Part 1 will consist of four
groups: Group 1 - A purposeful sample of 20 patients
with ‘controlled hypertension’ equally distributed by
gender (50% male and female), and age (18-35 yrs, 36-
55 yrs, 56 yrs and over) who were included in the
QUICK - I study; Group 2 -Ap u r p o s e f u ls a m p l eo f2 0
patients with ‘uncontrolled hypertension’ equally distrib-
uted by gender (50% male and female), and age (18-35
yrs, 36-55 yrs, 56 yrs and over) who were included in
QUICK - I study; Group 3 - Eight to ten healthcare pro-
fessionals treating patients with hypertension (HTN),
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Five to ten managers and doctors of the Health Mainte-
nance Organization (HMO) Hygeia.
Sample size and Recruitment
Sample size
For qualitative interviews, data saturation is a criterion
for calculation of the sample size. In general, about 20
interviews are required until saturation is reached and
no new information on the major themes is collected
[10,11]. For that reason we decided to interview 40
patients (20 with controlled and 20 with uncontrolled
hypertension). The number of interviews for HCP is
less because the number of health care professionals
working in the region is limited. The same accounts
for health insurance managers and doctors of Hygeia
HMO.
Patient recruitment
The patients in Groups 1 and 2 will be recruited among
participants in the QUICK - I study in the first month
after their inclusion. Health care professionals (Group
3); and managers and doctors working for Hygeia HMO
(Group 4) will be included in the first 3 months of
QUICK - I. Eligible respondents will be adequately
informed of the objectives of the qualitative study. Per-
mission for the interview and written or tape-recorded
informed consents will be taken.
Outcomes
The outcomes envisaged for part 1 include: (i) an over-
view of patients’ perceptions on CVD, CVD risk factors
and inhibiting or facilitating factors for CVD prevention
and care; (ii) an overview of perceptions of HCP, and
health insurance managers and doctors of Hygeia HMO
on barriers and facilitators to implementation of CVD
prevention and care; (iii) a protocol for CHEP; and (iv)
ap l a no fs u p p o r t i v es t r a t e g ies for implementation of
CHEP, including training for HCP.
Materials and measurements
In part one, patients allocated to Groups 1 and 2 will be
interviewed using a semi-structured questionnaire that
is based on a topic list used in a similar study by Beune
et al [12], but modified to suit the Nigerian setting.
Healthcare professionals from Groups 3 and 4 will simi-
larly be interviewed using semi structured question-
naires based on topic lists specifically designed to
address the particular concerns of these groups. A
researcher who speaks English and Yoruba fluently,
assisted by interpreters in Nupe, the other dominant
local language, will conduct interviews. CHEP will be
developed based on a systematic review of literature on
similar past patient education programs, and analysis of
the interview data.
Data management and analysis
Data entry and cleaning
The researcher will transcribe the semi-structured inter-
views conducted in part 1 and check unclear passages
with respondents, if needed.
Data analysis
The transcribed qualitative interview data will be ana-
lyzed using content analytical techniques: fragments
containing the respondents’ ideas about major themes,
for example inhibitors or facilitators of cardiovascular
diseases care, will be identified from each interview and
coded. Similar codes will be assigned to related state-
ments, resulting in a code list for each interview. Code
lists will be compared to identify common and unique
themes, leading to a thematic matrix for each group of
respondents. Similarities, variations and patterns
between groups will be compared, using these matrices.
Data entry and analysis will be supported by MAXQDA
software http://www.maxqda.com. MAXQDA facilitates
data management, the assignment of labels, codes and
themes to text fragments and the generation of thematic
matrices containing these elements. In the past,
MAXQDA software has been successfully used in similar
studies [13].
Part 2: Evaluation of Chep
Study population
To be included in the evaluation study of the effect of
CHEP (part 2), patients have to meet the following
inclusion criteria. They must: (i) be enrolled in HCHP;
(ii) be registered as a patient in OOH; (iii) be included
in the QUICK - I study for at least 12 months; (iv) have
a diagnosis of hypertension; (v) have uncontrolled BP
(≥140 mmHg systolic or ≥90 mmHg diastolic) or be non
adherent to prescribed medication or any other recom-
mended life style changes according to their score on
the Morisky scale [14]; and (vi) be ≥18 years of age.
Patients who meet these inclusion criteria will be
excluded if their treating health care professional judges
them unfit for participation (e.g. due to co morbidity) or
if they are not capable or unwilling to give informed
consent. Female patients who are pregnant or lactating
will be excluded from the entire study because the etiol-
ogy, prognosis and treatment regimes of gestational dia-
betes and pregnancy-induced hypertension are different
compared to hypertension and diabetes in non-pregnant
women.
To be included in the qualitative interviews for the
feasibility analysis, healthcare professionals must: (i) be a
HCP in OOH who participated in the implementation
of CHEP, or be managers and doctors of HCHP; and (ii)
give informed consent.
Table 1 shows an overview of the inclusion and exclu-
sion criteria for CHEP study. For an overview of the
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article of the QUICK - I study design [8].
Figure 1 describes the project populations for QUICK
- II and their relationship to the QUICK - I study.
Outcomes
The primary outcome of the evaluation of CHEP will be
t h ec h a n g e si na d h e r e n c et om e d i c a t i o no rl i f es t y l e
recommendations. This will be assessed through the
Morisky self-report medication adherence questionnaire
[14]. This scale asks patients to respond yes or no to
five questions. Each positive answer is assigned a score
of one, with higher scores indicating poorer adherence.
The same scale will be used for other life style recom-
mendations (e.g. salt intake). As such, self-reported
adherence will be assessed as a continuous measure.
Secondary outcomes are changes in physiological mea-
sures - systolic blood pressure, diastolic blood pressure,
and body mass index (BMI) or abdominal obesity at 6
months after baseline.
Table 2 indicates definitions of what we consider as
significant improvement per outcome measure.
Data will also be collected about other factors that
may influence patients’ hypertension management: self-
reported cardiovascular risk factors (physical activity,
diet, smoking, alcohol, sodium intake), knowledge of
HTN and HTN management, perceptions of HTN, per-
ceptions of medications, self efficacy, experienced stress,
patient satisfaction with care (e.g. doctors’ performance,
supply of medication, frequency of follow up, satisfac-
tion with CHEP etc).
Table 1 Inclusion and exclusion criteria for CHEP study
Inclusion Criteria Exclusion Criteria
Patients: Patients:
￿ Enrollment in HCHP ￿ Unwillingness to give
informed consent
￿ Registered and accessing care in
OOH
￿ Unfit for participation
(e.g. due to co morbidity)
￿ Inclusion in QUICK - I for at least
12 months
￿ Pregnant or lactating
females
￿ Diagnosis of hypertension
￿ Uncontrolled hypertension or non
adherence to prescribed
medication or lifestyle changes
after 12 months in QUICK - I
￿ Age of 18 years and over
￿ Give informed consent
Healthcare Professionals for interviews
on feasibility of CHEP:
￿ HCP of OOH who participated in
the implementation of CHEP, or
￿ Managers and Doctors of HCHP
￿ Give informed consent
Figure 1 Project populations and relationship between QUICK - I and CHEP study in QUICK - II.
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Sample size calculation
The power analysis for sample size is based on the dif-
ference between the adherence score after implementa-
tion of CHEP and the adherence score at baseline using
the 5-item Morisky adherence scale. Using the Morisky
distribution of low, medium, and high adherence ratios
of 32%, 52% and 16% respectively [14], and an estimated
post CHEP effect shift of 10% to a higher category, we
will need a minimum sample size of 150 patients.
Patient recruitment
The following steps will be applied in recruiting patients
for the CHEP study:
1. Researchers will use the records of the QUICK - I
study to identify all patients with uncontrolled
hypertension or with low or medium adherence
scores for medication or other life style measures on
the Morisky Scale at 12 months after inclusion into
the study.
2. Eligible patients will be informed about QUICK-II
and invited for participation through a written
invitation.
3. A research assistant will assess patients who are
interested in participating for eligibility criteria and
eligible patients will be asked to give informed
consent.
4. Patients who give informed consent will be invited
to a one-hour baseline assessment session.
5. Included patients who have completed baseline
assessments will be invited to have three CHEP
sessions spaced over a period of 4 months and one
final assessment interview six months after baseline.
To encourage participation, all included patients will
be reimbursed for extra travel costs incurred in visiting
for assessments and CHEP sessions outside their normal
clinic days.
Intervention
The intervention (CHEP) will be developed in part 1 of
this project. Subsequently, patients will be given (i)
three CHEP sessions over a period of four months con-
ducted by a trained nurse; (ii) audio-visual or written
educational materials containing specific information for
the target group and (iii) if necessary, referrals to regio-
nal facilities or initiatives that may help patients to
adopt healthier lifestyles.
Sessions
The first session will take place two weeks after the base-
line assessment interview, and the next two sessions will
occur one and three months thereafter. Clinical guide-
lines generally recommend a patient centred approach as
the preferred strategy for supporting patients in achieving
CVD treatment goals, such as adherence to prescribed
medication, dietary changes, and weight reduction,
reduced sodium intake, increased physical activity and
moderate use of alcohol [3]. While CHEP will use this
framework, it will have the additional aim of eliciting and
discussing culturally and socially specific aspects of
patients’ perceptions of cardiovascular risk factors and
treatment. This method is based on the work of Arthur
Kleinman [15], as well as more recent approaches to
improving adherence in hypertensive patients of various
ethnic and geographical background, such as those
recently developed in The Netherlands [16]. In short,
after identifying potential communication barriers and
establishing a rapport with the patient, it is expected that
the first session will focus on the patient’s beliefs about
hypertension. The next two sessions will deal with the
daily challenges they face in achieving hypertension treat-
ment goals within the broader context of their lives. Edu-
cation will take place in group training sessions.
Educational materials
Patients will also be given information leaflets or audio
visual materials that provide answers to frequently asked
questions about hypertension. These will be designed to
address the specific languages, customs, habits, norms
and dietary cultures that characterize the communities
of the patients participating in the program.
Supporting healthier lifestyles
If necessary, patients will be referred to initiatives offer-
ing healthier lifestyle support that is tailored to the target
group, based on a referral list that will be established for
this purpose in the first part of this study.
Table 2 Definitions of significant improvement per
outcome measure
Outcomes Significant improvement
Adherence to medication and life
style recommendations (Primary
outcomes)
Using the distribution on the
Morisky scale [14] of low, medium,
and high adherence ratios, a post
CHEP effect shift of 10% to a higher
category will be defined as a
significant improvement in
adherence.
Blood pressure (Secondary
outcome)
Blood pressure decrease of >10%
systolic or diastolic or blood
pressure at target level (patients
without diabetes or established
CVD: <140 mmHg systolic and <90
mmHg diastolic, patients with
diabetes, renal disease or
established CVD: <130 mm Hg
systolic and <80 mmHg diastolic).
Body mass index (kg/m
2 ) No CVD risk: <25
Moderate CVD risk: 25-30
High CVD risk: >30
In patients with a BMI >25 any
reduction of BMI at 6 months will
be regarded as an improvement.
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In order to ensure treatment fidelity and to avoid orga-
nizational- and healthcare-related obstacles to imple-
mentation, the nurses who will provide CHEP will be
given clear guidelines and extensive training in imple-
menting these guidelines.
Materials and Measurements
We will use the following measurements and materials
to evaluate the effects of CHEP: patients’ adherence to
medication and other life style recommendations will be
measured by using the five point Morisky Scale; and
patients’ blood pressure will be measured using pre vali-
dated OMRON M6 Comfort electronic equipment. The
blood pressure will be measured on 3 occasions with
the patient seated comfortably for 5 minutes, and the
last two values averaged. All other physiological mea-
sures will be performed according standardized proce-
dures using standard equipment. Other self-reporting
measures (see Table 3) will be measured using the ques-
tionnaire of the OHD 2 trial in the Netherlands [16].
A s p e c t so ft h i sq u e s t i o n n a i r ew i l lb ea d a p t e dt ot h e
Nigerian specifics where necessary.
All assessments will take place at baseline and 6
months after. A trained nurse will perform all physiolo-
gical assessments. A trained interviewer will perform
pre- and post CHEP assessment interviews. The
researcher will be responsib l ef o rt h et r a i n i n go ft h e
nurses and the interviewers.
Table 3 presents all the measurements that will be
used in the study.
Data Analysis
Statistical methods
The rate of adherence will be examined according to the
intention to treat principle. Primary and secondary out-
come measures will be calculated for every patient at
baseline and 6 months thereafter to assess possible
improvements. Furthermore, univariate and multi-level
analyses will be performed to evaluate the modifying
effect of the outcome measures (see above) on adher-
ence or blood pressure. If the N is sufficient, we will
perform separate subgroup analyses for gender. While a
p value of 0.05 will be the critical value for all analysis,
the p value will be adjusted for subgroup analysis
according to standard procedures.
Data from interviews with HCP will be analyzed and
used to identify potential barriers to the implementation
of CHEP in practice.
Ethical approval
Ethical approval was obtained for both QUICK studies
[8].
Discussion
Recent prevalence data from National Surveys indicate
that many risk factors for CVD are highly prevalent in
Nigeria: alcohol abuser/dependant - 4.4% (M - 8.1%, F -
0%); overweight/obesity (BMI ≥ 30 kg/m
2)-1 3 . 9 %( M-
5.5%, F - 21.1%); physical inactivity - 6.8%; tobacco use -
9.9% (M - 19.3%, F - 1.8%); raised cholesterol - (M -
10.4%, F - 21.6%); raised blood pressure (systolic ≥ 160
mmHg or diastolic ≥ 95 mmHg) - 12.4% (M - 12.1%, F
- 12.7%); and diabetes - 2.8% (M - 2.7%, F - 3%). There
are no data on dietary intake such as fruits and vegeta-
bles http://www.who.int/research/en/. A substantial
majority of CVD are preventable or treatable if patients
at risk have access to quality CVD prevention and care
programs. Quality care is, however, mostly inaccessible
in resource-limited settings. Even where such care may
be available and accessible, strict compliance and adher-
ence to the dictates of therapy regimes becomes para-
mount for the successful control of CVD risk factors,
and prevention of CVD in the affected populations. A
recent study in Kwara state, Nigeria where QUICK is
being implemented concluded that control of hyperten-
sion is unacceptably poor because of poor knowledge of
hypertension and adverse practices by patients [17]. In a
similar vein, another Nigerian study suggested that phy-
sicians should allocate special time for health education,
Table 3 Timelines and measures used in CHEP study
Measures Baseline Final
Physiological measures
- Clinic BP measurements, Heart rate X X
- Height, weight, Body Mass Index X X
- Hip and waist circumference X X
Self-reporting measures
- Patient demographics X
- Additional cardiovascular risk factors (physical activity,
diet, smoking, alcohol, sodium intake)
XX
- Medication adherence X X
- Adherence to lifestyle recommendations X
X
X
X
- Knowledge of HTN X X
- Perceptions of HTN X X
- Perceptions of medication X X
- Self efficacy X X
- Satisfaction with care X X
- Perception of stress X X
Case file data
- Prescribed medication X X
- Prescribed lifestyle measures X X
- Co-morbidity X X
Process data
- Records office visits, patient drop-out data etc X X
- HCP interviews X
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inadequate knowledge about hypertension by patients
are some of the potent barriers to effective CVD preven-
tion and care [18]. Furthermore, with particular refer-
ence to SSA where deep routed cultural practices still
play prominent roles in people’s lives, health education
to prevent CVD must be patient centered, and devel-
oped with due consideration for socio-cultural relevance
in order for the intervention to be successful. By
researching into the most optimal methods to imple-
ment an appropriately developed cardiovascular health
education program, our expectation is that the present
study will provide insight into, and contribute substan-
tially to the improvement in CVD management and out-
comes. We hope that the envisaged intervention, CHEP,
will become productively applicable not only in Nigeria,
but also in other similar settings in SSA and across the
globe.
The study has one notable limitation:
The design of our evaluation of CHEP could have
been improved by using a control group and a rando-
mized design. However, the study is conducted in a very
specific context, where it is impossible to avoid contami-
nation. For example, patients have generally long waiting
hours and may communicate about their condition or
the treatment with each other. Moreover, the number of
health care professionals in the clinic is limited such
that it would be impossible to randomize them into a
control and experimental condition. In addition, given
the context of the community health insurance program,
other clinics that provide standard cardiovascular care
are difficult to find in the region. Nevertheless, to
address this limitation, we consider analyzing the data
collected during QUICK - I study for the patients
included in QUICK - II to further compare and evaluate
the effects of CHEP.
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